Short Interest Update on Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals (SUPN) has 2,565,344 shares of shorts outstanding as on August 15, 2016, with 5 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 2,847,934 shares. The stock has a decent trading volume of 533,444 shares daily. The marginal decrease in the short positions is by -9.9%, which amounts to -282,590 shares. Short positions are 5.5% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.

Supernus Pharmaceuticals (NASDAQ:SUPN): The stock opened at $22.81 on Wednesday but the bulls could not build on the opening and the stock topped out at $23.18 for the day. The stock traded down to $21.73 during the day, due to lack of any buying support eventually closed down at $21.86 with a loss of -3.91% for the day. The stock had closed at $22.75 on the previous day. The total traded volume was 472,192 shares.


In a related news,The officer (VP, Chief Financial Officer) of Supernus Pharmaceuticals Inc, Patrick Gregory S sold 3,395 shares at $22 on July 14, 2016. The Insider selling transaction had a total value worth of $74,690. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.